Ortin Global (BOM:539287) EBIT: ₹-7.21 Mil (TTM As of Mar. 2026)


BOM:539287 Ortin Global Ltd BOM:539287
42 GF Score
Price ₹16.48
GF Value ₹2.54
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Ortin Global EBIT?

Ortin Global BOM:539287 -3.06% 42 EBIT is ₹-7.21 Mil as of Mar. 2026. GuruFocus rates BOM:539287 with a GF Score™ of 42/100 and a GF Value™ of ₹2.54 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Ortin Global's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹-0.08 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-7.21 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ortin Global's annualized ROC % for the quarter that ended in Mar. 2026 was -0.77%. Ortin Global's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -3.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ortin Global's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -5.23%.


Ortin Global  (BOM:539287) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ortin Global's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-0.308 * ( 1 - 0% )/( (0 + 40.029)/ 1 )
=-0.308/40.029
=-0.77 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Ortin Global's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.308/( ( (0 + max(0, 0)) + (0.05 + max(8.264, 0)) )/ 1 )
=-0.308/( ( 0 + 8.314 )/ 1 )
=-0.308/8.314
=-3.70 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.005 + 0 + 30.31) - (0.384 + 0 + 23.667)
=8.264

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ortin Global's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-7.212/137.996
=-5.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ortin Global EBIT Related Terms


Ortin Global EBIT Historical Data

* Premium members only.

The historical data trend for Ortin Global's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ortin Global EBIT Chart

Ortin Global Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 2.35 -66.12 -8.35 -7.21

Ortin Global Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.61 -1.63 -5.02 -0.50 -0.08

BOM:539287 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Global's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ortin Global EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ortin Global's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ortin Global's EV-to-EBIT falls into.


BOM:539287
42GF Score
Ortin Global Ltd BOM:539287
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ortin Global EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-7.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹-7.21 Mil mean?
Ortin Global (BOM:539287) has a EBIT of ₹-7.21 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ortin Global.
Is Ortin Global's EBIT too high?
Ortin Global's current EBIT is ₹-7.21 Mil. Overall, Ortin Global has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ortin Global's EBIT compare to ZTS and UTHR?
Ortin Global's EBIT of ₹-7.21 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ortin Global. Ortin Global's current EBIT is ₹-7.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ortin Global stock overvalued right now?
Based on GuruFocus' analysis, Ortin Global (BOM:539287) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.54, compared to a current price of ₹16.48 — trading 548.8% above its estimated fair value. The current EBIT is ₹-7.21 Mil. Ortin Global's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ortin Global (BOM:539287), the current EBIT is ₹-7.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ortin Global (BOM:539287) Overvalued in 2026?

Based on GuruFocus' analysis, Ortin Global stock appears to be overvalued. The current stock price of ₹16.48 is trading 548.8% above its estimated GF Value™ of ₹2.54. GuruFocus considers Ortin Global to be Significantly Overvalued.

Key valuation signals for BOM:539287:

  • EBIT: ₹-7.21 Mil
  • GF Value™: ₹2.54 vs. price of ₹16.48 (548.8% above fair value)
  • GF Score™: 42/100 with 8 warning signs

No single metric tells the full story. See the BOM:539287 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ortin Global Business Description

Other Exchanges ORTINGLOBE:India
Address G Block, Plot No. C-66, 9th Floor, 915, One BKC, Bandra Kurla Complex, Bandra East, Mumbai, MH, IND, 400051
Ortin Global Ltd is an Indian company engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helminthics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its API intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zidovudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others. Additionally, the company is also involved in the real estate business.
42GF Score

Get the complete analysis for BOM:539287

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹16.48
Price
₹2.54
GF Value